Baxter licenses pathogen safety product to Haemonetics
This article was originally published in Clinica
Executive Summary
Haemonetics is to pay up to $24.5 million to license the Intercept platelet system being developed jointly by Baxter International and Cerus to protect against the transmission of infectious diseases through platelet transfusion. As a result, Haemonetics will be able to "seamlessly integrate" its platelet collection devices with the Intercept platelet system.